About this Research Topic
Immunotherapy for cancer has revolutionized the treatment landscape for many tumors, and novel combination therapies are trialed daily. However, while some cancers respond, other do not, and this heterogeneity in responses can be seen within tumor types as well as within the same patient, with some tumors shrinking and others progressing. Similarly, the same treatment can lead to a variety of different immune-related adverse events (irAEs), with manifestations in different organs. In how far these differences of response and adverse events are related to the localization of the tumor, or the cell of origin and its underlying genetic make-up is still poorly understood for most cases.
Emerging data show that the immune landscape and the mechanisms used by tumors to escape anti-tumor immunity can differ widely based on the organ the tumor is localized in. If we can further our understanding of the differences in organ-specific immune landscapes we may be able to target a tumor not only based on its origin but on its homing tissue and the mechanisms at play that prevents successful interventions.
Within this Research Topic, we want to contrast and compare responses to immunotherapy of tumors of the same and diverse types found in various organs and get insights into how far the pre-existing immune microenvironment affects tumor immunity, and what role the type of cancer plays.
In this Research Topic we particularly welcome Original Research, Review, Mini-Review, Clinical Trial, and Perspective articles focusing on, but not limited to, the following subtopic:
• clinical experiences of mixed responses to immunotherapy within the same patient or patients with the same tumor type based on the location of the target lesions
• changes in irAEs based on target lesions
• characterization of the (tumor-) immune microenvironments across various organs
• advances in technologies to address differences in immune landscapes as well as novel concepts for fine-tuned therapeutic options that take organ-specific immunity into account.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Emerging data show that the immune landscape and the mechanisms used by tumors to escape anti-tumor immunity can differ widely based on the organ the tumor is localized in. If we can further our understanding of the differences in organ-specific immune landscapes we may be able to target a tumor not only based on its origin but on its homing tissue and the mechanisms at play that prevents successful interventions.
Within this Research Topic, we want to contrast and compare responses to immunotherapy of tumors of the same and diverse types found in various organs and get insights into how far the pre-existing immune microenvironment affects tumor immunity, and what role the type of cancer plays.
In this Research Topic we particularly welcome Original Research, Review, Mini-Review, Clinical Trial, and Perspective articles focusing on, but not limited to, the following subtopic:
• clinical experiences of mixed responses to immunotherapy within the same patient or patients with the same tumor type based on the location of the target lesions
• changes in irAEs based on target lesions
• characterization of the (tumor-) immune microenvironments across various organs
• advances in technologies to address differences in immune landscapes as well as novel concepts for fine-tuned therapeutic options that take organ-specific immunity into account.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Anti-cancer immunotherapy, organ-specific immunity, immune related adverse events, immuno-mapping, metastasis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
